Buprenorphine/naloxonea | Hydromorphoneb | ||
---|---|---|---|
Dosing | Total daily dose | Dosing | |
Day 1 (0–24 h) | 0.5 mg SL Q3H | 4 mg SL | 1–16 mg PO/SC/IV/IM Q1-3H PRN and titrate to effect (start at the lower end of dosing range) For 1st dose—Max 8 mg PO, or 4 mg SC/IV/IM |
Day 2 (24–48 h) | 1 mg SL Q3H | 8 mg SL | 1–16 mg PO/SC/IV/IM Q1-3H PRN and titrate to effect (start at the lower end of dosing range) |
Day 3 (48–72 h) | 8–16 mg SL once daily and 1–4 mg SL Q3H PRN | 8–16 mg SL; Max 32 mg SL including PRN | Discontinued |
Day 4 (72–96 h) | Consolidate day 3 total dose to once daily dosing | Max 32 mg SL | Discontinued |